tiprankstipranks
Advertisement
Advertisement
Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
PremiumCompany AnnouncementsCrispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
25d ago
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
Premium
The Fly
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
1M ago
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
1M ago
CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated
PremiumRatingsCRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated
1M ago
Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)
Premium
The Fly
Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)
1M ago
Reaffirming Buy on CRISPR Therapeutics: Conference Engagement and Gene-Editing Leadership Support Attractive Risk‑Reward
Premium
Ratings
Reaffirming Buy on CRISPR Therapeutics: Conference Engagement and Gene-Editing Leadership Support Attractive Risk‑Reward
2M ago
Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
PremiumMarket NewsCathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
3M ago
Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today
Premium
The Fly
Cathie Wood’s ARK Investment buys 113K shares of Crispr Therapeutics today
3M ago
CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF
Premium
Market News
CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100